Alliancebernstein L.P. bought a new stake in InVitae Corp (NASDAQ:NVTA) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 23,700 shares of the medical research company’s stock, valued at approximately $227,000. Alliancebernstein L.P. owned about 0.06% of InVitae Corp at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also modified their holdings of NVTA. Donald L. Hagan LLC boosted its stake in InVitae Corp by 30.0% during the 2nd quarter. Donald L. Hagan LLC now owns 13,000 shares of the medical research company’s stock worth $124,000 after acquiring an additional 3,000 shares during the last quarter. American International Group Inc. boosted its stake in InVitae Corp by 31.3% during the 1st quarter. American International Group Inc. now owns 17,174 shares of the medical research company’s stock worth $190,000 after acquiring an additional 4,090 shares during the last quarter. Metropolitan Life Insurance Co. NY bought a new position in InVitae Corp during the 1st quarter worth approximately $256,000. Credit Suisse AG boosted its stake in InVitae Corp by 22.9% during the 1st quarter. Credit Suisse AG now owns 25,178 shares of the medical research company’s stock worth $279,000 after acquiring an additional 4,694 shares during the last quarter. Finally, State of Wisconsin Investment Board bought a new position in InVitae Corp during the 2nd quarter worth approximately $277,000.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/11/13/23700-shares-in-invitae-corp-nvta-acquired-by-alliancebernstein-l-p.html.
A number of research analysts have weighed in on NVTA shares. Zacks Investment Research lowered shares of InVitae Corp from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. BidaskClub lowered shares of InVitae Corp from a “buy” rating to a “hold” rating in a research note on Thursday, October 26th. Leerink Swann cut their price target on shares of InVitae Corp from $14.00 to $12.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 7th. Finally, J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a $15.00 price target (up previously from $14.00) on shares of InVitae Corp in a research note on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $13.50.
InVitae Corp (NASDAQ NVTA) opened at $8.62 on Monday. InVitae Corp has a fifty-two week low of $5.76 and a fifty-two week high of $11.88.
InVitae Corp Company Profile
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.